Danaher (DHR) Tops Q2 EPS by 40c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Danaher (DHR) Tops Q2 EPS by 40c

KeyBanc Remains Positive on Life Sciences as 'Strong' Earning Season Begins with Danaher (DHR) Report

July 21, 2022 11:40 AM EDT

KeyBanc analyst Paul Knight comments "Bioprocess market leaders Sartorius (SRT3) and Danaher (DHR) published 2Q22 results this morning with strong revenue and EPS beats, providing a positive backdrop for the industry at large. Results clearly indicate bioprocess companies are witnessing high-levels of demand, making up for the headwinds posed... More

UBS on Danaher (DHR): 'we believe the CPHD platform will continue to see traction as COVID-19 becomes endemic'

July 21, 2022 11:24 AM EDT

UBS analyst Elizabeth Garcia reiterated a Buy rating and $297.00 price target on Danaher (NYSE: DHR).

The analyst comments "DHR kicked off 2Q22 life sciences tools earnings and reported a 2Q beat driven by the base business (+8% vs. +MSD% guidance) and COVID (+1.5% vs. -LSD... More

Cowen Reiterates Outperform Rating on Danaher (DHR), 'We expect the stock to react favorably'

July 21, 2022 10:22 AM EDT

Cowen analyst Dan Brennan reiterated an Outperform rating and $343.00 price target on Danaher (NYSE: DHR).

The analyst comments "Total organic growth of 9.5% well ahead of 'LSD%' guide and our 1.8%, with organic growth ex COVID testing ('base growth') of 8.0% ahead of our 4.3%.... More

Stifel Reiterates Hold Rating on Danaher (DHR), 'we are impressed with the company's ability to perform'

July 21, 2022 10:21 AM EDT

Stifel analyst Daniel Arias reiterated a Hold rating and {REMOVEPT} price target on Danaher (NYSE: DHR).

The analyst comments "Danaher reported 2Q22 revenues of $7.75B (+7.5% y/y), which was above Stifel ($7.12B) and consensus ($7.31B). Core revenue growth of 9.5% was ahead of expectations on... More